Ani Pharmaceuticals (ANIP) Operating Expenses (2010 - 2026)

Ani Pharmaceuticals has disclosed Operating Expenses across 17 years of filings, most recently posting $225.6 million for Q2 2026.

• In Q2 2026, Operating Expenses rose 14.23% year-over-year to $225.6 million; the TTM figure through Jun 2026 stood at $828.0 million (up 13.09% YoY), while the FY2025 annual figure was $772.3 million, up 25.82% from the prior year.
• Operating Expenses came in at $225.6 million for Q2 2026 at Ani Pharmaceuticals, up from $198.6 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $225.6 million in Q2 2026 to a low of $83.7 million in Q1 2022.
• Average Operating Expenses over 5 years is $144.5 million, with a median of $128.9 million recorded in 2023.
• Year-over-year, Operating Expenses soared 62.55% in 2022 and increased 8.9% in 2025.
• Over 5 years, Operating Expenses stood at $92.4 million in 2022, then soared by 35.19% to $124.9 million in 2023, then soared by 56.05% to $195.0 million in 2024, then rose by 8.9% to $212.3 million in 2025, then grew by 6.26% to $225.6 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $225.6 million in Q2 2026, $198.6 million in Q1 2026, and $212.3 million in Q4 2025.